Send to

Choose Destination
Int J Pharm. 2013 May 1;448(1):28-43. doi: 10.1016/j.ijpharm.2013.03.006. Epub 2013 Mar 15.

Second generation liposomal cancer therapeutics: transition from laboratory to clinic.

Author information

School of Medical Science and Technology, Indian Institute of Technology, Kharagpur 721302, India.


Recent innovations and developments in nanotechnology have revolutionized cancer therapeutics. Engineered nanomaterials are the current workhorses in the emerging field of cancer nano-therapeutics. Lipid vesicles bearing anti-tumor drugs have turned out to be a clinically feasible and promising nano-therapeutic approach to treat cancer. Efficient entrapment of therapeutics, biocompatibility, biodegradability, low systemic toxicity, low immunogenicity and ability to bypass multidrug resistance mechanisms has made liposomes a versatile drug/gene delivery system in cancer chemotherapy. The present review attempts to explore the recent key advances in liposomal research and the vast arsenal of liposomal formulations currently being utilized in treatment and diagnosis of cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center